LAS VEGAS (KTNV) — A COVID-19 vaccine produced by Johnson & Johnson has been showing mixed but promising results in its third phase of global trials released by the company.
Johnson & Johnson said the vaccine had 85% efficacy in severe coronavirus cases and 66% efficacy in moderate and severe cases.
RELATED: UPDATE: No appointments left for vaccination clinic at Doolittle Community Center
While less effective than the Moderna and Pfizer-Biontech vaccines already released to the market, the Johnson and Johnson vaccine would be easier to access and distribute.
The company said their vaccine doesn't need to be stored in an ultra-cold environment, it's cheaper than alternatives, and it only requires one dose to be effective.
Chief Medical Adviser Dr. Anthony Fauci said the vaccine if approved, could be yet another tool in the fight against the coronavirus.
"There essentially were no hospitalizations or deaths in the vaccine group," he said, "this really tells us that we have now a value-added additional vaccine candidate."
The vaccine could increase accessibility in Southern Nevada where demand has greatly outstripped supply.
Health officials are urging people to remain vigilant until vaccines are more widely available by practicing social distancing, good hygiene, and wearing a mask.
